ClinicalTrials.gg
Active, not recruitingNCT06388564Updated Oct 15, 2026

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

A Phase 2 interventional study of Axatilimab and Ruxolitinib in Chronic Graft-versus-host-disease, sponsored by Incyte Corporation. Active, not recruiting at 68 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Updated Oct 15, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.

Enrollment
3rd of 10
130 · median 50
Started
2024
with 1 other
Phase 2
5 of 10
4 open now
Registered
4th of 10
by date
Lead sponsor
5 of 10
Incyte Corporation

Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 3rd largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 4th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About axatilimab

axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

03

Conditions studied

  • Chronic Graft-versus-host-disease

Keywords

  • cGVHD
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 12 years of age at the time of .
  • New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy.
  • History of 1 allo-SCT (any type of stem cell donor, any conditioning regimen, and source of hematopoietic stem cells).
  • Adequate hematologic function independent of transfusion and growth factors for at least 7 days prior to study entry: ≥ 0.75 × 109/L and platelet count ≥ 20 × 109/L.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Received more than 1 prior allo-SCT. Prior HCT is allowed.
  • Has overlap cGVHD, defined as simultaneous presence of features or characteristics of aGVHD in a patient with cGVHD.
  • Received previous systemic treatment for cGVHD, including systemic and extracorporeal photopheresis.
  • Received systemic corticosteroids within 2 weeks prior to C1D1, regardless of indication.
  • Initiated systemic treatment with CNIs or mTOR inhibitors within 2 weeks prior to C1D1.
  • Prior treatment with a JAK inhibitor within 8 weeks before randomization. Participants who received a JAK inhibitor for the treatment of aGVHD are eligible only if they achieved a response (CR or PR) to JAK inhibitor treatment and did not discontinue due to toxicity.
  • Evidence of relapse of the primary hematologic disease or treatment for relapse after the allo-SCT was performed, including DLIs for the treatment of molecular relapse.
  • History of acute or chronic pancreatitis.
  • History of thromboembolic events (such as deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction) in the 6 months prior to study entry.
  • Active symptomatic myositis.
  • Severe renal impairment, that is, estimated \< 30 mL/min measured or calculated by Cockcroft-Gault equation in adults and Schwartz formula in pediatric participants, or end-stage renal disease on dialysis. Participants with CrCl of 30 to 59 mL/min on treatment with fluconazole are not eligible.
  • Impaired liver function, defined as total > 1.5 × and/or and AST > 3 × ULN in participants with no evidence of liver cGVHD.
  • Currently active significant cardiac disease, such as uncontrolled arrhythmias, uncontrolled hypertension, or Class 3 or 4 congestive heart failure as defined by , or a history of myocardial infarction or unstable angina within 6 months prior to randomization.
  • Pregnant or breastfeeding.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    Treatment Group A

    Axatilimab will be administered at a protocol defined starting dose plus ruxolitinib at a protocol defined starting dose.

    Drug: Axatilimab · Drug: Ruxolitinib

  • Experimental
    Treatment Group B

    Ruxolitinib will be administered at a protocol defined starting dose.

    Drug: Ruxolitinib

  • Experimental
    Treatment Group C

    Corticosteroids alone will be administered at a protocol defined starting dose.

    Drug: Corticosteroids

Interventions

  • Axatilimab will be administered at protocol defined dose.

  • Ruxolitinib will be administered at protocol defined dose.

  • DrugCorticosteroids

    Corticosteroids will be administered at protocol defined dose.

    Also known as: prednisone, prednisolone, methylprednisolone

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Defined as Complete Response (CR) or Partial Response (PR) at 6 months in the absence of new systemic therapy for cGVHD. Response assessment will be based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.

    Time frame: 6 months

Secondary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study treatment.

    Time frame: Up to 2 years and 30 days

  2. Duration of Response

    Defined as the time from the first response (PR or CR) to the date of progression of cGVHD, start of new systemic therapy or death from any cause.

    Time frame: Up to 2 years

  3. Proportion of participants with a ≥ 7-point improvement in modified Lee symptom scale (mLSS) score

    Time frame: Up to 2 years

  4. Best overall response in the first 6 months

    Define as PR or CR in the first 6 months.

    Time frame: Up to 6 months

  5. OR at 12 months, defined as CR or PR at 12 months (C14D1) in the absence of new systemic therapy for cGVHD.

    Defined as CR or PR at 12 months in the absence of new systemic therapy for cGVHD

    Time frame: 12 months

  6. Proportion of participants who remain corticosteroid-free

    Time frame: 4 weeks, 8 weeks and 6 months

  7. Organ-specific response in the first 6 cycles and on study, based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.

    Based on the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD.

    Time frame: Up to 2 years

  8. Failure-free Survival (FFS)

    Defined as the time from date of randomization to date of initiation of a new cGVHD treatment, malignancy relapse, or death due to any cause.

    Time frame: Up to 2 years and 30 days

  9. Axatilimab pharmacokinetic (PK) in Plasma

    Axatilimab concentration in plasma.

    Time frame: Up to 2 years and 30 days

  10. Ruxolitinib PK in Plasma

    Ruxolitinib concentration in plasma.

    Time frame: Up to 2 years and 30 days

07

Study locations

68 sites
08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Oct 2026, 23 months.

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jun 2027 → Oct 2026 and completion Dec 2029 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Apr 29, 2024
StartActual
Oct 11, 2024
Primary completionActual
Oct 1, 2026was Jun 2027
CompletionEst.
Mar 30, 2029was Dec 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2027→Oct 1, 2026 (actual)
Oct 15, 2026
Study completion
Dec 1, 2029→Mar 30, 2029
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Primary completion Jun 1, 2027→Oct 1, 2026 (now actual)
    Study completion Dec 1, 2029→Mar 30, 2029
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06388564
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Oct 11, 2024
Primary completion
Oct 1, 2026
Completion
Mar 30, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Axatilimab · Ruxolitinib

Start the discussion